Physician profile
Michael Jon Mattice
NPI 1821075219
$296.77
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.61 · 2020: $30.00 · 2021: $154 · 2022: $81.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $80.11 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $52.55 | 2021 | |
| Biogen, INC. | $42.89 | 2021 | |
| Carestream Dental, LLC | $31.61 | 2019 | |
| Hu-Friedy Mfg. Co., LLC | $30.00 | 2020 | |
| Genzyme Corporation | $25.11 | 2022 | |
| Novo Nordisk INC | $19.10 | 2021 | |
| Adamas Pharmaceuticals, INC. | $15.40 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mattice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.